Isomorphic Labs Secures $2.1 Billion Series B Funding to Advance AI-Driven Drug Discovery

May 13, 2026 11:14 CST Updated 11:14

Isomorphic Labs

AI Drug Developer

On May 12, Isomorphic Labs, the AI-driven pharmaceutical leader under Alphabet, officially announced the successful completion of a $2.1 billion Series B financing round. This follows the company’s $600 million Series A funding in 2025 and marks another significant capital injection. It also stands as one of the largest single financing deals in the global AI pharmaceutical sector in 2026, fully demonstrating the long-term confidence and strong belief of investors in the AI-powered drug discovery field.

Top Capital Clusters Enter the Market, with Cumulative Financing Reaching $2.7 Billion

The lineup of this round of financing is nothing short of luxurious, led by Thrive Capital, with existing shareholders such as Alphabet and GV (Google Ventures) continuing to invest their support. Additionally, it has attracted a group of new investors, including MGX, Temasek, CapitalG, and the UK Government’s AI Fund, maximizing the level of capital endorsement.

Isomorphic Labs, founded in 2021 by Demis Hassabis, the founder of Google DeepMind, has rapidly grown into a benchmark enterprise in the AI pharmaceuticals field, leveraging the robust technical resources and platform advantages of Alphabet. With the addition of this Series B financing round, the company's cumulative external funding scale has reached 2.7 billion US dollars, firmly establishing it among the most well-funded and highest-valued AI pharmaceutical startups globally.

Funding Focuses on Two Core Areas: IsoDDE Engine + Clinical Pipeline Advancement

The company's core competitiveness stems from the AlphaFold 3 artificial intelligence model, jointly developed with Google DeepMind—this model can accurately predict the three-dimensional structures of biomolecules and their interactions, providing a revolutionary tool for drug target discovery and candidate molecule design, significantly shortening the R&D cycle and reducing R&D costs.

Officially disclosed, the $2.1 billion raised this time will be entirely focused on two core development directions, precisely targeting breakthroughs in the bottlenecks of AI pharmaceutical technology implementation:

1. Fully develop and scale the deployment of the autonomous AI drug design engine IsoDDE, creating an end-to-end AI R&D platform covering the entire drug development process to achieve iterative upgrades in R&D efficiency.

2. Accelerate the clinical translation process of the company's proprietary R&D pipeline, successfully achieving the critical leap from "AI-designed drug candidates" to "clinical validation of their efficacy," and promoting the implementation of technological achievements.

Technology gains recognition from major pharmaceutical companies, partnerships established with Eli Lilly and Novartis

With leading AI pharmaceutical technology, Isomorphic Labs has successfully gained recognition from top global pharmaceutical companies. It has currently entered into deep collaborations with two giants, Eli Lilly and Novartis, and has been commissioned to utilize AlphaFold technology to discover small-molecule drug candidates for undisclosed drug targets.

This collaboration marks that the company's AI drug discovery approach has successfully broken through the technical validation stage, officially entering a critical period of industrial implementation, and has gained mainstream recognition in the global biopharmaceutical industry.

Voices from All Parties: The AI-First Approach Has Been Validated, Accelerating the Progress of Conquering Diseases

Demis Hassabis stated that the successful completion of this $2.1 billion financing round represents global investors' high recognition of the company's "AI-first" R&D approach, which has now been practically validated for its feasibility. The next step will be to fully promote the scaled application of AI pharmaceutical technologies, fulfilling the corporate mission of "tackling all diseases."

Alphabet and Google President Ruth Porat also spoke highly of Isomorphic Labs' progress, noting its significant achievements in the field of AI-driven drug discovery. This substantial financing round will further advance its technology translation, bringing more innovative treatments to market faster and benefiting patients.

Industry Watch: AI Drug Development Enters Critical Period of Technology Implementation

The current global new drug development faces industry pain points such as high costs and R&D cycles lasting over 10 years, while AI technology is the core key to breaking this efficiency bottleneck. Isomorphic Labs' recent acquisition of $2.1 billion in substantial funding not only provides sufficient financial support for its own technology development and pipeline advancement but also injects strong confidence into the entire AI pharmaceuticals industry.

As core AI pharmaceutical technologies such as AlphaFold 3 continue to mature, and more AI-designed drug candidates enter clinical stages, the AI pharmaceuticals industry is expected to experience explosive growth in the next 3-5 years, fundamentally reshaping the development landscape of the global biopharmaceuticals industry.

Reference Source:https://www.fiercebiotech.com/biotech/alphabets-ai-biotech-isomorphic-labs-bags-21b-series-b-fuel-next-gen-drug-design-model

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!

Please indicate: Name + Research Direction!

Edition

Authority

Sound

Ming

All reproduced articles in this official account are intended to convey more information, with clear attribution of sources and authors. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the authors, not this site.